Jackson Square Capital LLC Sells 963 Shares of McKesson Co. (NYSE:MCK)

Jackson Square Capital LLC decreased its stake in shares of McKesson Co. (NYSE:MCK - Free Report) by 44.0% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 1,227 shares of the company's stock after selling 963 shares during the period. Jackson Square Capital LLC's holdings in McKesson were worth $699,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in MCK. Wolff Wiese Magana LLC increased its holdings in shares of McKesson by 742.9% in the third quarter. Wolff Wiese Magana LLC now owns 59 shares of the company's stock worth $29,000 after purchasing an additional 52 shares during the period. MidAtlantic Capital Management Inc. purchased a new stake in shares of McKesson in the 3rd quarter valued at about $29,000. RPg Family Wealth Advisory LLC bought a new stake in shares of McKesson during the 3rd quarter valued at about $31,000. ORG Wealth Partners LLC purchased a new position in shares of McKesson during the third quarter worth about $40,000. Finally, Bruce G. Allen Investments LLC increased its position in shares of McKesson by 51.9% in the fourth quarter. Bruce G. Allen Investments LLC now owns 82 shares of the company's stock worth $47,000 after purchasing an additional 28 shares during the last quarter. Institutional investors own 85.07% of the company's stock.

Insider Transactions at McKesson

In other news, EVP Leann B. Smith sold 579 shares of the business's stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $572.79, for a total value of $331,645.41. Following the sale, the executive vice president now directly owns 864 shares in the company, valued at $494,890.56. The trade was a 40.12 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 0.11% of the company's stock.

McKesson Stock Performance

Shares of McKesson stock traded down $2.50 on Friday, hitting $592.69. 686,346 shares of the company traded hands, compared to its average volume of 622,630. The business has a 50-day simple moving average of $595.11 and a 200 day simple moving average of $561.17. McKesson Co. has a 52 week low of $464.42 and a 52 week high of $637.51. The stock has a market capitalization of $75.24 billion, a P/E ratio of 30.69, a price-to-earnings-growth ratio of 1.26 and a beta of 0.52.

McKesson (NYSE:MCK - Get Free Report) last announced its quarterly earnings results on Wednesday, November 6th. The company reported $7.07 EPS for the quarter, topping the consensus estimate of $6.88 by $0.19. The business had revenue of $93.65 billion for the quarter, compared to analysts' expectations of $89.33 billion. McKesson had a net margin of 0.77% and a negative return on equity of 207.50%. The business's quarterly revenue was up 21.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned $6.23 EPS. Research analysts expect that McKesson Co. will post 32.73 earnings per share for the current year.

McKesson Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, January 2nd. Shareholders of record on Monday, December 2nd were paid a $0.71 dividend. This represents a $2.84 dividend on an annualized basis and a yield of 0.48%. The ex-dividend date was Monday, December 2nd. McKesson's payout ratio is 14.71%.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on MCK shares. Leerink Partners cut their price target on shares of McKesson from $665.00 to $630.00 and set an "outperform" rating for the company in a research note on Monday, October 7th. StockNews.com raised McKesson from a "hold" rating to a "buy" rating in a research note on Wednesday, November 6th. Citigroup dropped their price target on McKesson from $713.00 to $677.00 and set a "buy" rating for the company in a research note on Friday, January 10th. Evercore ISI raised their price objective on McKesson from $560.00 to $680.00 and gave the company an "outperform" rating in a report on Thursday, November 7th. Finally, Mizuho initiated coverage on McKesson in a research note on Wednesday, December 4th. They issued a "neutral" rating and a $630.00 target price for the company. Two equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $646.14.

McKesson Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.